

09/926571

77 Rec'd PCT/PTO 20 NOV 2001

FORM PTO-1390
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

11137/04808

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.

PCT/US00/13389

INTERNATIONAL FILING DATE

15 MAY 2000 (15.05.00)

PRIORITY DATE CLAIMED

20 MAY 1999 (20.05.99)

TITLE OF INVENTION

ISOFLAVONOID METHYLATION ENZYME

APPLICANT(S) FOR DO/EO/US

Richard A. DIXON and Xian Z. HE

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information: Statement under WIPO Standard ST.25

U.S. APPLICATION NO. **09/926571**

INTERNATIONAL APPLICATION NO.
PCT/US00/13389

ATTORNEY'S DOCKET NUMBER
11137/04808

21. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO **\$1040.00**

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO **\$890.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$740.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 890

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	72 - 20 =	52	x \$18.00	\$ 936
Independent claims	19 - 3 =	16	x \$84.00	\$ 1344
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$ 280
TOTAL OF ABOVE CALCULATIONS =				\$ 3580

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2.

+

SUBTOTAL = \$ 1790

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE = \$ 1790

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

\$

TOTAL FEES ENCLOSED = \$ 1790

Amount to be
refunded:

\$

charged:

\$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 18-1260 in the amount of \$ 1790 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 18-1260. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Eugenia S. Hansen
Sidley Austin Brown & Wood
717 N. Harwood, Suite 3400
Dallas, Texas 75201
United States of America

SIGNATURE

Karen L. Knezek

NAME

39,253

REGISTRATION NUMBER

Rec'd PCT/PTO 20 NOV 2001

ISOFLAVONOID METHYLATION ENZYME**TECHNICAL FIELD OF THE INVENTION**

The invention relates to gene manipulation in plants.

BACKGROUND OF THE INVENTION

The isoflavonoids of the Leguminosae are among the most important biologically active classes of phenylpropanoid-derived plant natural products. Isoflavones such as daidzein, genistein and biochanin A exhibit a wide range of pharmacological effects including estrogenic, antiangiogenic, antioxidant and anticancer activities (Dixon, R.A. 1999. "Isoflavonoids: biochemistry, molecular biology and biological functions." In U. Sankawa, eds, *Comprehensive Natural Products Chemistry*, Elsevier, pp 773-823), and the health promoting activity of high soy diets are believed to reside in their isoflavone components (Barnes, et al. 1990. "Soybeans inhibit mammary tumors in models of breast cancer." In M.W. Pariza, eds, *Mutagens and Carcinogens in the Diet*, Wiley-Liss, Inc, New York, pp 239-253; Adlercreutz, et al. 1991. "Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet," *Am J Clin Nutr* 54: 1093-1100; Lee, et al. 1991. "Dietary effects on breast-cancer risk in Singapore," *Lancet* 337: 1197-1200). Daidzein and genistein act as precursors in the biosynthesis of various antimicrobial isoflavonoid phytoalexins in a wide variety of legumes (Dixon, R.A. and N.L. Paiva. 1995. "Stress-induced phenylpropanoid metabolism," *Plant Cell* 7: 1085-1097). Furthermore, due to their estrogenic activity, high levels of isoflavonoids such as the phytoestrogen formononetin can adversely affect the reproductive capacity of sheep grazing forage legumes (Shutt, D.A. 1976. "The effects of plant oestrogens on animal reproduction," *Endeavour* 75: 110-113).

Isoflavonoids have been ascribed key roles in plant-pathogen interactions because many have quite strong antimicrobial activity. Antimicrobial isoflavonoids fall into two functional classes, the pre-formed "phytoanticipins" and the inducible "phytoalexins" (VanEtten, et al. 1994. "Two classes of plant antibiotics: phytoalexins versus phytoanticipins," *The Plant Cell* 6: 1191-1192). Examples of the former class include the prenylated isoflavones of lupin, which are synthesized in various organs of the plant during

seedling development (Ingham, et al. 1983. "Fungitoxic isoflavones from *Lupinus albus* and other *Lupinus* species," *Zeitschrift für Naturforschung*, C 38: 194-200). Examples of the latter include several pterocarpan, the biosynthesis of which has been studied in detail, particularly in the cases of phaseollin, medicarpin, pisatin and glyceollin from bean, alfalfa, pea and soybean, respectively (Dixon, R. A. 1999. "Isoflavonoids: biochemistry, molecular biology and biological functions," *Comprehensive Natural Products Chemistry*, Vol. 1, U. Sankawa, ed, Elsevier, pp. 773-823).

Isoflavonoid compounds have been shown to accumulate in infected plant cells to levels known to be antimicrobial in vitro. The temporal, spatial and quantitative aspects of accumulation are consistent with a role for these compounds in disease resistance (Rahe, J.E. 1973. "Occurrence and levels of the phytoalexin phaseollin in relation to delimitation at sites of infection of *Phaseolus vulgaris* by *Colletotrichum lindemuthianum*," *Can J Botany* 51: 2423-2430; Hadwiger, L.A. and D.M. Webster. 1984. "Phytoalexin production in five cultivars of pea differentially resistant to three races of *Pseudomonas syringae* pv. *Pisi*," *Phytopathology* 74: 1312-1314; Long, et. al. 1985. "Further studies on the relationship between glyceollin accumulation and the resistance of soybean leaves to *Pseudomonas syringae* pv. *Glycinea*," *Phytopathology* 75: 235-239; Bhattacharyya, M.K. and E.W. Ward. 1987. "Biosynthesis and metabolism of glyceollin I in soybean hypocotyls following wounding or inoculation with *Phytophthora megasperma* f. sp. *Glycinea*," *Physiol Mol Plant Pathol* 31: 387-405). Inhibition of the synthesis of glyceollin by application of an inhibitor of L-phenylalanine ammonia-lyase (PAL) to soybean seedlings breaks resistance to *Phytophthora megasperma* f. sp. *glycinea* (Moesta, P. and H. Grisebach. 1982. "L-2-Aminoxy-3-phenylpropionic acid inhibits phytoalexin accumulation in soybean with concomitant loss of resistance against *Phytophthora megasperma* f. sp. *Glycinea*," *Physiol Plant Pathol* 21: 65-70). Isolates of the fungal pathogen *Nectria hematococca* with reduced ability to degrade the pea phytoalexin pisatin have reduced virulence on pea, suggesting that pisatin is functionally involved in the disease resistance response (Kistler, H.C. and H.D. VanEtten. 1984. "Regulation of pisatin demethylation in *Nectria haematococca* and its influence on pisatin tolerance and virulence," *J Gen Micro* 130: 2605-2613).

Phytoalexins accumulate more rapidly, and to higher levels, during resistant interactions between a plant and its microbial pathogens than during susceptible interactions

that result in disease (Dixon, R.A., and M.J. Harrison. 1990. "Activation, structure and organization of genes involved in microbial defense in plants," *Adv Genet* 28: 165-234). Therefore, increasing the rate at which phytoalexins accumulate, and the absolute levels attained, would result in increased resistance (Lamb, et al. 1992. "Emerging strategies for enhancing crop resistance to microbial pathogens," *Bio/technology* 10: 1436-1445).

Certain methylated forms of isoflavones, for example formononetin (7-hydroxy-4'-methoxyisoflavone) and biochanin A (5, 7-dihydroxy-4'-methoxyisoflavone) have been shown to provide a nutraceutical benefit. For example, biochanin A and formononetin are reported to be phytoestrogens, and biochanin A has been shown to be effective in animal cancer study models. (Yangihara, et al. 1993. "Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract," *Cancer Res* 53:5815-5821; and Zhou-Jin-Rong, et al. 1998. "Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis," *Cancer Res* 58: 5231-5238).

As seen from the above examples, genetic manipulation of isoflavonoid biosynthesis in transgenic plants would positively impact plant, animal and human health (Dixon, et al. 1999. "Molecular controls for isoflavonoid biosynthesis in relation to plant and human health," *Recent Advances in Phytochemistry* 33: 133-160). However, the enzymes responsible for increasing isoflavonoid phytoalexin accumulation have not been identified, and not all the genes encoding the enzymes of isoflavonoid phytoalexin biosynthesis have been cloned.

The biosynthetic branch pathway leading to isoflavones in plants involves a cytochrome P450 mediated 2-hydroxylation/aryl migration of a flavanone intermediate formed from phenylpropanoid- and acetate-derived precursors via the chalcone synthase and chalcone isomerase reactions (Fig. 1) (Kochs, G. and H. Grisebach. 1986. "Enzymic synthesis of isoflavones," *Eur J Biochem* 155: 311-318; Hakamatsuka, et al. 1991. "P-450-dependent oxidative rearrangement in isoflavone biosynthesis: reconstitution of P-450 and NADPH:P450 reductase", *Tetrahedron* 47: 5969-5978; Steele, et al. 1999. "Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean," *Arch Biochem Biophys* 367: 146-150; and Jung, et al. 2000. "Identification and expression of isoflavone synthase: the key enzyme for biosynthesis of

isoflavones in legumes," *Nature Biotechnology* 18:208-212). After aryl migration, the 2-hydroxy isoflavanone intermediate undergoes dehydration to yield the corresponding isoflavone (Hakamatsuka, et al. 1998. "Purification of 2-hydroxyisoflavanone dehydratase from the cell cultures of *Pueraria lobata*," *Phytochemistry* 49: 497-505). Genistein (4', 5, 7-trihydroxyisoflavone) is the product of aryl migration/dehydration of naringenin (4', 5, 7-trihydroxyflavanone), whereas daidzein (4', 7-dihydroxyisoflavone) is formed in a similar manner from liquiritigenin (4', 7-dihydroxyflavanone). 4'-O-Methylation of daidzein yields formononetin (7-hydroxy-4'-methoxyisoflavone), whereas 4'-O-methylation of genistein yields biochanin A (5, 7-dihydroxy-4'-methoxyisoflavone), an important anticancer compound found in chickpea (Yanagihara, et al. 1993. "Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract," *Cancer Res* 53: 5815-5821) (Fig. 1).

In alfalfa and certain other legumes such as chickpea, methylation of the 4'-hydroxyl is a prerequisite for further substitutions of the isoflavonoid nucleus leading to pterocarpan phytoalexins such as medicarpin (Dixon, R.A. 1999. "Isoflavonoids: biochemistry, molecular biology and biological functions," In U. Sankawa, eds, *Comprehensive Natural Products Chemistry*, Elsevier, pp 773-823). This reaction is important biotechnologically, because it represents a pathway entry point for conversion of isoflavones with human anticancer activity into downstream metabolites with antifungal activity for the plant. However, the exact mechanism of this O-methylation reaction has remained unclear. Based on radiolabeling studies in copper-induced alfalfa seedlings in which formononetin, but surprisingly not daidzein, was incorporated into the pterocarpan medicarpin, it has been proposed that the 4'-O-methylation might be an integral part of the aryl migration reaction of isoflavone biosynthesis (Dewick, P.M. and M. Martin. 1979. "Biosynthesis of pterocarpan, isoflavan and coumestan metabolites of *Medicago sativa* : chalcone, isoflavone and isoflavanone precursors," *Phytochemistry* 18: 597-602). However, aryl migration occurs in vitro in the absence of methylation (Kochs, G. and H. Grisebach. 1986. *Eur J Biochem* 155: 311-318; Hakamatsuka, et al. 1991. *Tetrahedron* 47: 5969-5978; Kessmann, et al. 1990. "Stress responses in alfalfa (*Medicago sativa* L.) III. Induction of medicarpin and cytochrome P450 enzyme activities in elicitor-treated cell suspension cultures and protoplasts," *Plant Cell Rep* 9: 38-41; Steele, et al. 1999. "Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean,"

Arch Biochem Biophys 367: 146-150), and mutants of subterranean clover exist in which formononetin and biochanin A are virtually absent, and daidzein and genistein accumulate instead (Wong, E. and C.M. Francis. 1968. "Flavonoids in genotypes of *Trifolium subterraneum*-II. Mutants of the Geraldton variety," *Phytochemistry* 7: 2131-2137),

5 indicating that the isoflavones are the natural substrates for 4'-O-methylation. The problem has also been compounded by the fact that it has not proven possible to purify a S-adenosyl-L-methionine (SAM) dependent O-methyltransferase (OMT) that can catalyze 4'-O-methylation of daidzein. Instead, the SAM-dependent isoflavone OMT from alfalfa (He, X-Z and R.A. Dixon. 1996. "Affinity chromatography, substrate/product specificity and amino acid sequence analysis of an isoflavone O-methyltransferase from alfalfa (*Medicago sativa* L.)," *Arch Biochem Biophys* 336: 121-129) produces 7-O-methyldaidzein (isoformononetin) in vitro by methylation of the hydroxyl group at the 7-position. Isoformononetin is a rarely occurring plant natural product that has not been reported from alfalfa.

15 The isoflavone 7-OMT has been cloned from alfalfa and the recombinant enzyme converts daidzein exclusively to isoformononetin when expressed in *E. coli* (He, et al. 1998. "Stress responses in alfalfa (*Medicago sativa* L.) XXII. cDNA cloning and characterization of an elicitor-inducible isoflavone 7-O-methyltransferase," *Plant Mol Biol* 36: 43-54). This enzyme activity, and its corresponding transcripts, are strongly induced in elicited alfalfa cell cultures coordinately with other enzymes of medicarpin biosynthesis (Dalkin, et al. 20 1990. "Stress responses in alfalfa (*Medicago sativa* L.) I. Elicitor-induction of phenylpropanoid biosynthesis and hydrolytic enzymes in cell suspension cultures," *Plant Physiol* 92: 440-446; He, et al. 1998. *Plant Mol Biol* 36: 43-54).

A large number of plant OMT sequences are now available in the databases, most of which encode enzymes that act on hydroxycinnamic acid intermediates of lignin biosynthesis or on flavonoid derivatives (Ibrahim, et al. 1998. "Plant O-methyltransferases: molecular analysis, common signature and classification," *Plant Mol Biol* 36: 1-10; Joshi, C.P. and V.L. Chiang. 1998. "Conserved sequence motifs in plant S-adenosyl-L-methionine-dependent methyltransferases," *Plant Mol Biol* 37: 663-674). In nearly all cases, the enzymes exhibit strict regiospecificity; for example, a series of distinct, position-specific 25 OMTs is involved in the synthesis of polymethylated flavonols in *Chrysosplenium americanum* (Ibrahim, et al. 1987. "Enzymology and compartmentation of polymethylated 30

flavonol glucosides in *Chrysosplenium americanum*,” *Phytochemistry* 26: 1237-1245; Gauthier, et al. 1996. “cDNA cloning and characterization of a 3’/5’-*O*-methyltransferase for partially methylated flavonols from *Chrysosplenium americanum*,” *Plant Mol Biol* 32: 1163-1169). However, some OMTs appear to be more versatile, acting on both flavonoids and hydroxycinnamic acids (Gauthier, et al. 1998. “Characterization of two cDNA clones which encode *O*-methyltransferases for the methylation of both flavonoid and phenylpropanoid compounds,” *Arch Biochem Biophys* 351: 243-249), or are specific for more than one related substrate, such as the well-studied caffeic acid/5-hydroxyferulic acid OMTs of lignin biosynthesis (Bugos, et al. 1991. “cDNA cloning, sequence analysis and seasonal expression of lignin-bispecific caffeic acid/5-hydroxyferulic acid *O*-methyltransferase of aspen,” *Plant Mol Biol* 17: 1203-1215; Li, et al. 2000. “5-Hydroxyconiferyl aldehyde modulates enzymatic methylation for syringyl monolignol formation, a new view of monolignol biosynthesis in angiosperms,” *J Biol Chem* 275: 6537-6545). However, there have been no reports of OMTs, or any other plant natural product biosynthetic enzymes, that exhibit different regiospecificity in vivo and in vitro.

Utilizing the different regiospecificity of isoflavone 7-OMT in vivo, it is now possible to genetically manipulate biologically active 4’-*O*-methylated isoflavonoids.

SUMMARY OF THE INVENTION

In one aspect the invention is a method for increasing the level of at least one 4’-*O*-methylated isoflavonoid compound in a target plant comprising transforming the target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic plant and over-expressing the isoflavone *O*-methyltransferase gene in the transgenic plant under the control of a suitable constitutive or inducible promoter. In particular, the 4’-*O*-methylated isoflavonoid compound can be a 4’-*O*-methylated isoflavonoid phytoalexin or a 4’-*O*-methylated isoflavonoid nutraceutical. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In another aspect, the invention is a method for producing at least one 4’-*O*-methylated isoflavonoid compound in a target plant that does not produce the 4’-*O*-methylated isoflavonoid compound comprising transforming the target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic plant and

expressing said isoflavone *O*-methyltransferase gene in said transgenic plant under the control of a suitable constitutive or inducible promoter, wherein the transgenic plant contains all the other necessary enzymes of isoflavonoid biosynthesis to produce the 4'-*O*-methylated isoflavonoid compound. In particular, the 4'-*O*-methylated isoflavonoid compound can be a 4'-*O*-methylated isoflavonoid phytoalexin or a 4'-*O*-methylated isoflavonoid nutraceutical. The target plant can possess native DNA encoding the other necessary enzymes for isoflavonoid biosynthesis. Alternatively, if the target plant lacks a necessary enzyme, it can be transformed with a DNA fragment encoding the deficient enzyme. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In another aspect, the invention is a method for producing at least one 4'-*O*-methylated isoflavonoid nutraceutical in non-plant cell system by expression of a DNA fragment comprising an isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter in cells that have been genetically transformed to contain all the other necessary enzymes of isoflavonoid biosynthesis to make the 4'-*O*-methylated isoflavonoid nutraceutical. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In another aspect, the invention is a method for decreasing the levels of formononetin, at least one of its conjugates or mixtures thereof in a transgenic forage legume such as alfalfa comprising antisense expression or sense gene-mediated silencing using a DNA fragment comprising an isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter. Alternatively, the isoflavone *O*-methyltransferase could be down-regulated by nucleic acid-mediated insertional inactivation. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In another aspect, the invention is a method for decreasing the levels of at least one 4'-*O*-methylated isoflavonoid compound in a target plant having all the necessary enzymes for synthesizing said 4'-*O*-methylated isoflavonoid compound comprising transforming the

target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic plant and inducing antisense expression, sense gene-mediated silencing, or nucleic acid-mediated insertional inactivation of the isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter. This method is useful for decreasing compounds selected from the group consisting of a 4'-*O*-methylated isoflavonoid phytoalexin, a 4'-*O*-methylated isoflavonoid phytoalexin conjugate and mixtures thereof. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In another aspect, the invention is a method for decreasing the level of at least one 4'-*O*-methylated isoflavonoid nutraceutical, at least one 4'-*O*-methylated isoflavonoid nutraceutical conjugate or mixtures thereof in a target plant having all the necessary enzymes for synthesizing the 4'-*O*-methylated isoflavonoid nutraceutical or conjugate comprising transforming the target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic plant and inducing antisense expression or sense gene-mediated silencing of the isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter, thereby increasing the level of the corresponding non-methylated precursor, its conjugate or mixture thereof. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In another aspect, the invention is a method for the production of a 7-*O*-methylated isoflavonoid compound comprising contacting intact plants or cell suspension cultures with a non-methylated isoflavone precursor of the 7-*O*-methylated isoflavonoid compound, with the intact plants or cell suspension cultures transformed with a DNA fragment comprising an isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In another aspect, the invention is a method for the production of a 7-*O*-methylated isoflavonoid compounds comprising contacting a soluble or immobilized isoflavone *O*-methyltransferase enzyme with a non-methylated isoflavone precursor to the 7-*O*-methylated isoflavonoid compound, wherein the enzyme is produced by expression of a

DNA fragment comprising the corresponding isoflavone *O*-methyltransferase gene in transgenic plants or a heterologous system. In a preferred embodiment, the heterologous system is selected from the group consisting of transfected bacterial, yeast and insect cells. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In yet another aspect, the invention is an antiserum against 4'-*O*-methyltransferase used as a reagent for determining transgene expression of said 4'-*O*-methyltransferase in plants.

In yet another aspect, the invention is a method of increasing disease resistance in a target plant by transforming the target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene, wherein the transformed plant exhibits increased levels of 4'-*O*-methylated isoflavonoids when compared to levels of 4'-*O*-methylated isoflavonoids in plants of the same species which do not comprise the DNA fragment. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

In yet another aspect, the invention is a composition comprising at least one 4'-*O*-methylated isoflavonoid suitable for administration as a food stuff, a nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical, wherein the 4'-*O*-methylated isoflavonoid is isolated from at least a portion of a transgenic plant transformed with a DNA fragment comprising an isoflavone *O*-methyltransferase gene and wherein the transgenic plant exhibits increased levels of 4'-*O*-methylated isoflavonoids when compared to levels of 4'-*O*-methylated isoflavonoids in plants of the same species which do not comprise the DNA fragment. In a preferred embodiment, the DNA fragment used to transform the plant comprises SEQ ID NO:1 or a sequence exhibiting at least moderate hybridization with SEQ ID NO:1. An exemplary plant is a legume.

In another aspect, the invention is a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein the plant upon expression of the gene exhibits increased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise the recombinant DNA

sequence. The invention also includes seed, progeny, and progeny from the seed from this transgenic plant.

In another aspect, the invention is a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein the plant upon expression of the gene exhibits decreased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise the recombinant DNA sequence. The invention also includes seed, progeny, and progeny from the seed from this transgenic plant.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts pathways for the formation and *O*-methylation of isoflavones in plants. The flavanones naringenin and liquiritigenin are formed by the action of chalcone synthase and chalcone isomerase, with loss of the 5-hydroxyl in liquiritigenin occurring by co-action of chalcone reductase with chalcone synthase. Aryl migration of the B-ring is catalyzed by 2-hydroxyisoflavanone synthase leading, after dehydration, to daidzein or genistein. Conversion of formononetin to medicarpin proceeds via 2'-hydroxylation, reduction and ring closure steps (Dixon, R. A. 1999. In U. Sankawa, ed, *Comprehensive Natural Products Chemistry*, Elsevier, pp 773-823).

Fig. 2 depicts the nucleotide sequence for the alfalfa isoflavone 4'-*O*-methyl transferase (IOMT)8 cDNA (SEQ ID NO:1).

Fig. 3A-3B depicts generation and molecular analysis of transgenic alfalfa altered in expression of IOMT. Fig. 3A depicts the binary vector constructs harboring IOMT sequences in sense and antisense orientations. Fig. 3B depicts enzymatic activity of IOMT in leaf tissue from untransformed "C" and empty vector transformed "V" controls, and a range of IOMT8 sense transformants.

Fig. 4A-4D depicts the metabolism of daidzein after infiltration into untreated alfalfa leaves. Fig. 4A and 4B depict high pressure liquid chromatography (HPLC) profiles of phenolic compounds from leaves of empty vector control plant #62C and IOMT sense transgenic line #69 24 hr after infiltration with Pi buffer, respectively. Fig. 4C and 4D depict HPLC profiles of leaf extracts from the same vector control and sense transgenic

lines, respectively, 24 hr after feeding daidzein in Pi buffer by leaf infiltration. Fig. 4E and 4F show UV spectra of 2', 4, 4'-trihydroxychalcone and isoformononetin, respectively.

Fig. 5A-5H depict abiotic elicitation of isoflavonoid compounds in control and IOMT over-expressing transgenic alfalfa. Fig. 5A and 5B are HPLC profiles of leaf extracts from CuCl₂-treated plants of vector control line #9C and IOMT over-expressing line #67, respectively, 32 hr after exposure to 3 mM CuCl₂. Peaks labeled 1-4 were identified as apigenin conjugate, 7, 4'-dihydroxyflavone, 7, 4'-dihydroxyflavanone and apigenin aglycone, respectively. Fig. 5C and 5D are HPLC profiles of leaf extracts from plants of vector control line #9C and IOMT over-expressing line #67, respectively, 32 hr after transfer of seedlings to water. Fig. 5E and 5G depict levels of formononetin and Fig. 5F and 5H depict levels of medicarpin in leaves of replicate vegetatively propagated vector control lines #9C and #62C (control lines) and IOMT over-expressing lines #67 and #69, 32 hr after exposure to H₂O or 3 mM CuCl₂.

Fig. 6A-6F depict accumulation of isoflavonoid compounds in response to fungal infection in control and IOMT over-expressing transgenic alfalfa. Fig. 6A and 6B are HPLC profiles of extracts from *Phoma medicaginis* infected leaves of empty vector control line #64C and IOMT over-expressing line #67, respectively at 12 hr post-inoculation. Fig. 6C and 6D are HPLC profiles of extracts from uninoculated leaves of line #64C and #67, respectively. Fig. 6E and 6F depict levels of formononetin glucoside or medicarpin, respectively, in leaves of replicate vegetatively propagated vector control (line #64C) and IOMT over-expressing (lines #67 and #69) plants at various times after inoculation with *P. medicaginis*.

Fig. 7A-7B depict accumulation of isoflavonoid compounds in control and putatively IOMT gene-silenced transgenic alfalfa. Levels of formononetin glucoside (Fig. 7A) and medicarpin (Fig. 7B) were measured in leaves from replicate cuttings of vector control line #56C and IOMT sense transformant #78 20hr after inoculation with spores of *Phoma medicaginis*.

Fig. 8A-8B depict disease resistance of transgenic alfalfa modified in expression of isoflavone *O*-methyltransferase. Fig. 8A depicts sizes of 100 individual lesions on leaves of empty vector control line #64C and IOMT over-expressing line #69, measured 5 days post-inoculation. The average value for the size of the wounds produced by the tracing wheel

alone for a parallel series of 100 wound sites has been subtracted. The solid lines show the means for the control lines and the dashed lines show the means for the IOMT over-expressing lines. The bars show the standard deviations. Fig. 8B depicts sizes of 100 individual lesions on leaves measured 5 days post-inoculation as described above, but showing lesions on IOMT over-expressing line #67 and the empty vector control line #64C infected in parallel.

DETAILED DESCRIPTION

By using reverse genetic and ectopic expression approaches in transgenic alfalfa, it has now been found that the alfalfa isoflavone OMT is involved in the formation of a different product in vivo (formononetin) compared to in vitro (isoformononetin). Because of the in vivo regiospecificity of the alfalfa isoflavone OMT, the levels of formononetin in transgenic plants can now be genetically manipulated for the purpose of reducing levels of this compound and thereby improving forage quality. In another embodiment, transgenic reduction of isoflavone 4'-O-methylation can also be used to increase the levels of the immediate precursors of this reaction, daidzein and genistein, which are important nutraceuticals. It is shown herein that isoflavone OMT functions operationally as a rate-limiting enzyme for production of the antimicrobial phytoalexin medicarpin in infected alfalfa leaves, such that over-expression of isoflavone OMT in transgenic alfalfa causes a significant increase in the levels of medicarpin following infection by a pathogenic fungus, leading to strongly increased disease resistance. The functional identification of the alfalfa IOMT has now made possible methods for increasing or decreasing the levels of formononetin or other 4'-O-methylated isoflavonoid nutraceuticals such as biochanin A, texasin, afrormosin, and pseudobaptigenin in plants that produce these compounds, and for increasing the levels of medicarpin or related 4'-O-methylated isoflavonoid phytoalexins such as maackiain or pisatin and thereby improving disease resistance. Thus, transgenic expression of isoflavone OMT in legumes can be used to engineer both phytoalexin levels for improved disease resistance and health promoting nutraceutical phytochemicals. Furthermore, IOMT can also be used to engineer isoflavone 4'-O-methylation in plants, or other organisms, that do not naturally produce isoflavonoids, but have been engineered to do so by introduction of the necessary isoflavone synthase.

To demonstrate that isoflavone *O*-methyltransferase (IOMT) is involved in the production in vivo of formononetin, and therefore medicarpin, which is derived from formononetin by the pathway shown in Fig. 1, transgenic alfalfa plants were made which either under- or over-expressed IOMT as follows.

Example 1: Construction and Characterization of Expression Plasmids Containing Exemplary IOMT cDNA

The full-length alfalfa IOMT8 cDNA (SEQ ID NO:1 and Fig. 2) was placed in the sense and antisense orientations under control of the cauliflower mosaic virus 35S promoter for constitutive expression in alfalfa. All recombinant DNA techniques were performed as described in Sambrook et al. (Sambrook, et al. 1989. *Molecular Cloning. A Laboratory Manual* (2nd Ed), Cold Spring Harbor Laboratory Press, New York). For sense vector construction, the expression plasmid pET15b / IOMT8, which contains the full-length IOMT8 cDNA (He, et al. 1998. *Plant Mol Biol* 36: 43-54), was digested with *Bam*HI and *Nco*I. A 1.2 Kb fragment was isolated and subcloned into the *Nco*I and *Bam*HI sites of plasmid pRTL2 (Restrepo, et al. 1990. "Nuclear transport of plant polyviral proteins," *Plant Cell* 2: 987-998). For antisense vector construction, the full length IOMT8 cDNA was amplified by polymerase chain reaction (PCR) using the following primers:

5'-GGGTACCTGGATAGATCTCAATAAGAGA-3' (SEQ ID NO:2) and 5'-CGCGGATCCATGGCTTCATCAATTAATGG-3' (SEQ ID NO:3), with added *Kpn*I and *Bam*HI restriction sites, and the PCR product was digested with *Kpn*I and *Bam*HI prior to cloning into pRTL2. Plasmids containing IOMT sequences in pRTL2 were digested with *Hind*III, and 2.2 kb fragments containing the cauliflower mosaic virus 35S promoter, tobacco etch virus 5' untranslated leader sequence, IOMT sequence and CaMV terminator, were isolated and ligated into the *Hind*III site of the binary vector pGA482 (An, G. 1986.

"Development of plant promoter expression vectors and their use for analysis of differential activity of nopaline synthase promoter in transformed tobacco cells," *Plant Physiol* 81: 86-91). The constructs were mobilized into *Agrobacterium tumefaciens* strain LBA4404 by electroporation (Cell-porator, GIBCO BRL, Gaithersburg, MD). The gene constructs, utilizing the intermediate plasmid pRTL2 and the binary vector pGA482, are shown in Fig.

3A.

Example 2: Genomic Insertion of IOMT Transgene by Transformation of Alfalfa

Alfalfa (*Medicago sativa* L. cv. Regen SY) was transformed and regenerated through somatic embryogenesis using kanamycin (25 mg/L) as selectable marker (Thomas, et al. 1990. "Selection of interspecific somatic hybrids of *Medicago* by using *Agrobacterium* - transformed tissue," *Plant Sci* 69: 189-198). Trifoliolate leaves were surface-sterilized for 10 sec in 70% ethanol and for 15 min in 1% (v/v) sodium hypochlorite solution containing 0.1% Tween 20 and then immersed for 10-15 min in a suspension of *Agrobacterium* LBA4404 harboring the IOMT constructs or empty vector (control). After rinsing with distilled water, tissues were blotted on a paper towel and plated on MS medium (Murashige, T. and Skoog, F. 1962. "A revised media for rapid growth and bioassay with tobacco tissue culture," *Physiol Plant* 15:473-497) containing B5 vitamins, 0.25 g/l casein hydrolysate, 10 μ M 2,4-dichlorophenoxyacetic acid (2,4-D), 5 μ M 6-benzylaminopurine (BAP), 0.1 mM acetosyringone, and 30 g/l sucrose (A1 medium). After 3 day co-cultivation, tissues were transferred to the above medium but containing 2 μ M BAP, 500 μ g/ml carbenicillin, 25 μ g/ml kanamycin and no acetosyringone (A2 medium). Four weeks after subculture, calli were transferred to A2 medium with addition of 30 mM L-proline but no BAP (A3 medium) for embryo development. Somatic embryos were transferred to A3 medium without 2,4 D (A4 medium) for embryo germination. Seedlings that developed were finally transferred to A4 medium without casein hydrolysate and proline for rooting. Potted kanamycin-resistant plantlets were maintained in the greenhouse.

After plant regeneration via somatic embryogenesis as described above, transformants were analyzed by polymerase chain reaction (PCR) for genomic insertion of IOMT transgene sequences. Genomic DNA was extracted according to Edwards et. al. (Edwards, et al. 1991. "A simple and rapid method for the preparation of plant genomic DNA for PCR analysis," *Nucleic Acids Res* 19: 1359). Leaf tissues of transformants were extracted in 200 mM Tris-HCl, pH7.5, 250 mM NaCl, 25 mM ethylenediaminetetraacetic acid (EDTA), 0.5% sodium dodecyl sulfate (SDS), centrifuged for 5 min in a microfuge, and supernatants transferred to fresh Eppendorf tubes to which equal amounts of 2-propanol were added. After incubation for 2 min at room temperature, DNA was precipitated by centrifugation. Pellets were resuspended in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0. PCR reactions were performed in 50 μ l volumes containing 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.25 mM $MgCl_2$, 200 μ M dNTPs, 0.5 units of Taq polymerase, 0.4 μ M oligonucleotide

primers and 200 ng of plant DNA. PCR amplification of IOMT sequences was performed with 5' (5'-GGCCATATGGCTTCATCAATTATGGC-3') (SEQ ID NO:4) and 3' (5'-CGGGATCCTTATGGATAGATCTCAA-3') (SEQ ID NO:5) sequences of IOMT8 as primers. A Perkin Elmer Cetus 480 thermocycler was used for the amplification with 35 cycles of denaturation (94 °C for 1 min), annealing (55 °C for 1 min), and extension (72 °C for 1 min with a 5 min extension for the last cycle). Controls included DNA from empty vector transformed and non-transformed plants. More than 70% of the transformants contained the full length IOMT cDNA insert (data not shown). All the transgenic lines produced were phenotypically normal. Genomic integration of the transgene was confirmed in a subset of the transformants by Southern-blot analysis. To perform this, genomic DNA was isolated from leaf tissues (Edwards, et al. 1991. *Nucleic Acids Res* 19: 1359), digested with *EcoRI* or *HindIII*, subjected to electrophoresis through a 0.8% agarose gel and transferred to a Hybond-N membrane (Amersham, Piscataway, NJ) by capillary blotting. The membrane was hybridized with ³²P-labeled 800 bp IOMT probe (from nucleotide 249 to 1035 of SEQ ID NO:1 and Fig. 2) and washed in 0.2 x SSC, 0.1% SDS at 42 °C for 20 min and 3 times for 30 min at 65 °C. Sense transformants #52, #61, #62, #67, #69 and #78 had a higher transgene copy number than the other lines analyzed. Southern blot analysis following digestion with *HindIII* and hybridization with the T-DNA left border indicated that the individual transformants resulted from independent integration events.

Example 3: Confirmation of IOMT Transgene by Use of Polyclonal Antiserum Against Alfalfa IOMT

IOMT transcripts are not expressed in healthy alfalfa leaves (He, et al. 1998. *Plant Mol Biol* 36: 43-54), and therefore, demonstration of the presence of IOMT activity in leaves confirms the expression of the IOMT transgene. Leaf tissue extracts from representative sense transformants and vector control transgenic alfalfa plants were, therefore, subjected to western blot analysis, using a polyclonal antiserum against alfalfa IOMT expressed in *E. coli*, to assess levels of ectopic expression of the enzyme in leaves. Polyclonal antiserum against IOMT was produced by immunizing rabbits (Covance Research Products Inc., Denver, PA) with the protein antigen expressed from *E. coli* (He, et al. 1998. *Plant Mol Biol* 36: 43-54). Protein extracts from leaf tissues were solubilized in sample buffer (25 mM Tris-HCl, pH 6.8, 1% SDS, 2.5% 2-mercaptoethanol, 5% glycerol). Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes

(Amersham, Piscataway, NJ) by electrophoretic blotting in transfer buffer (25 mM Tris-HCl, pH 8.3, 150 mM glycine, 20% v/v methanol). Blots were probed using polyclonal antiserum against purified alfalfa IOMT as primary antibody, with anti-(rabbit IgG)-peroxidase conjugate as secondary antibody. The IOMT signal was detected by exposing the blots to X-ray film shortly after incubation with ECL reagent (Amersham, Piscataway, NJ). While all of the sense transformants exhibited the presence of IOMT protein, Lines #67 and #69 exhibited the highest IOMT protein levels.

Example 4: Effects of Transgenically Expressed IOMT

IOMT enzyme activity was measured in extracts from leaf tissues taken from plants maintained in the greenhouse. IOMT activity was analyzed as previously described (He, X-Z and R. A. Dixon. 1996. *Arch Biochem Biophys* 336: 121-129). Leaf tissues were ground into powder in liquid nitrogen, and extracted in enzyme assay buffer (200 mM Tris-HCl, pH 8.3, 5 mM EDTA, 14 mM 2-mercaptoethanol, 10% PVPP). After centrifugation, supernatants were used for enzyme activity assay. The reaction mixtures contained 100 nmol daidzein, 300 nmol S-[³H-methyl] adenosyl-L-methionine and enzyme extract in a total volume of 120 µl. Reactions were carried out at 30°C for 30 min and terminated by addition of 100 µl acetic acid. The reaction mixtures were extracted with 0.5 ml ethyl acetate, the ethyl acetate evaporated under N₂, and the residue resuspended in methanol. For product analysis, the re-suspended residue was applied to silica gel thin layer chromatography (TLC) plates (Si250; Baker, Philipsburg, NJ). Following development in chloroform: methanol: triethylamine (8:1:1, v/v), the product of interest was scraped from the TLC plates and radioactivity quantified by liquid scintillation counting. For product analysis by HPLC, 20 µl of re-suspended residue was applied to a C18 column (5 µm particle size, 4.6 mm x 250 mm) and eluted with a gradient of increasing solvent B in solvent A (solvent A, 1% phosphoric acid in water; solvent B, acetonitrile: 0-40 min, 20-45% B; 40-42 min, 45-95% B). The eluate was monitored at 287 nm. Identity of products was confirmed by co-elution and diode array analysis of UV spectra with authentic samples of formononetin and isoformononetin.

Several independent transgenic lines harboring the IOMT sense construct expressed high IOMT activity (Fig. 3B). However, lines #62 and #78, with high transgene copy

number, did not express IOMT activity. There was a direct relationship between the levels of IOMT protein determined by immunoblotting and the extractable activity of the enzyme from leaves. TLC and HPLC analysis of the labeled product formed from daidzein and S-[³H-methyl] adenosyl-L-methionine showed that only isoformononetin was produced by the enzyme extracted from healthy, non-transformed alfalfa leaves (data not shown), consistent with the previously ascribed function of the enzyme as an isoflavone 7-O-methyltransferase.

Alfalfa roots accumulate formononetin malonyl glucoside (FMG), medicarpin, and medicarpin malonyl glycoside (MMG) (Sumner, et al. 1996. "High-performance liquid chromatography/continuous-flow liquid secondary ion mass spectrometry of flavonoid glucosides in leguminous plant extracts," *J Mass Spectrom* 31: 472-485). To determine whether down-regulation of IOMT affects the levels of these compounds in roots, extraction and HPLC analysis of phenolic compounds was performed as described previously (Dalkin, et al. 1990. *Plant Physiol* 92: 440-446). Equal amounts of tissue were ground in liquid N₂ and extracted twice with acetone overnight at room temperature. The extracts were centrifuged at 3,000 rpm for 30 min and the supernatants collected. The acetone was evaporated under N₂, and the residue dissolved in methanol. Insoluble material was removed by centrifugation at 12,000 x g for 30 min. Twenty µl of the solution was applied to a C18 HPLC column (5 µm particle size, 4.6 mm x 250 mm) and eluted with a gradient of increasing solvent B (solvent A, 1% phosphoric acid in water; solvent B, acetonitrile: 0-40 min, 20-45% B; 40-42 min, 45-95% B). The absorbance of the eluant was monitored at 287 nm. Retention times and calibration curves for formononetin, isoformononetin, medicarpin and conjugates were established with authentic samples. HPLC analysis of root extracts from greenhouse grown plants indicated that the levels of formononetin, FMG and MMG were highly variable, making it difficult to determine whether differences in metabolite levels were significant. Therefore, for analysis of antisense transgenic lines, plants selected initially on the basis of metabolite levels were vegetatively propagated and grown under growth chamber conditions. Three independent antisense lines #42, #54 and #60 exhibited significantly reduced levels of these compounds compared to the average values from a population of 46 independently propagated control plants, by 33% to 44% for FMG, by 29% to 71% for medicarpin and by 18% to 51% for MMG. The above results indicate that expression of IOMT antisense constructs reduces constitutive root isoflavone levels.

A number of independent alfalfa transformants with strong ectopic expression of IOMT in the leaves were analyzed for levels of constitutive isoflavonoid intermediates. The isoflavonoid pathway is only significantly expressed in alfalfa leaves following stress such as infection or elicitation (Higgins, V.J. 1972. "Role of the phytoalexin medicarpin in three leaf spot diseases of alfalfa," *Physiol Plant Pathol* 2: 289-300; Paiva, et al. 1994. "Regulation of isoflavonoid metabolism in alfalfa," *Plant Cell, Tissue and Organ Cult* 38: 213-220), and therefore, in the absence of induction of the enzymes that produce early isoflavonoid pathway substrates, the HPLC profiles of IOMT over-expressing and control leaves were identical (Fig. 4A and 4B). No isoformononetin was detected. A minor compound running very close to the retention time of isoformononetin in extracts from Pi buffer treated leaves of control and IOMT over-expressing plants, and daidzein-fed leaves of control plants, was shown to be 2',4,4'-trihydroxychalcone, an intermediate of flavonoid biosynthesis (Fig. 4 A-4C). However, isoformononetin was produced on feeding unlabeled daidzein to leaves of IOMT over-expressing transgenic alfalfa (Fig. 4D), whereas the daidzein remained unconverted when fed to leaves of control plants (Fig. 4C). Thus, the regiospecificity of IOMT in planta is identical to that displayed in vitro if the substrate is exogenously supplied to unstressed tissues, again consistent with the designation of the enzyme as an isoflavone 7-O-methyltransferase.

Cuttings were taken from sense lines #67 and #69, and from a range of untransformed and empty vector control lines, and propagated in the growth chamber. To induce the enzymes of the isoflavonoid pathway, trifoliolate leaves were elicited by exposure to 3 mM CuCl₂ taken up through the cut petioles for 8 hours at room temperature. This is a reliable method for induction of isoflavonoid accumulation in alfalfa (Dewick, P.M. and Martin, M. 1979. "Biosynthesis of pterocarpans and isoflavan phytoalexins in *Medicago sativa* : the biochemical interconversion of pterocarpan and 2'-hydroxyisoflavans," *Phytochemistry* 18: 591-596). Trifoliolate leaves were placed on 2 layers of moist filter paper in a petri dish and incubated for a further 24 hours. Levels of induced isoflavonoids were then determined by HPLC as described above. Leaves that had not been exposed to copper contained no detectable formononetin or medicarpin, as depicted in Fig. 5C and 5D. Copper treatment led to a modest induction of formononetin and medicarpin in the various control lines, but to much stronger induction in the IOMT over-expressing lines (Fig. 5A and 5B).

Analysis of replicate cuttings from each of the lines clearly indicated that over-expression of IOMT in elicited alfalfa leaves leads to a significant increase in the levels of formononetin and medicarpin if the isoflavonoid pathway is first induced by elicitation (Fig. 5C and 5H). Importantly, when the IOMT activity was measured in extracts from control or CuCl₂-elicited leaves of the various lines, the product was always isoformononetin, indicating that CuCl₂ itself does not affect the regiospecificity of the enzyme. No isoformononetin was observed in any of the elicited leaf samples.

The above experiments were repeated using infection by spores of *Phoma medicaginis*, a treatment that induces the enzymes of the isoflavonoid pathway and consequent medicarpin accumulation in alfalfa leaves (Paiva, et al. 1994. *Plant Cell, Tissue and Organ Cult* 38: 213-220). Metabolite profiles for leaves from control empty vector and IOMT over-expressing (line #67) plants after exposure to *P. medicaginis* are shown in Fig. 6A and 6B, respectively. Fungal infection led to appearance of formononetin glucoside and medicarpin in the control lines (Fig. 6A), but much stronger induction in the IOMT over-expressing lines (Fig. 6B), and no isoformononetin was observed in any of the infected leaf samples (Fig. 6B). No formononetin glucoside or medicarpin were observed in uninfected control plants (Fig. 6C and 6D). Analysis of replicate cuttings from each of the lines, harvested at various time after fungal infection, clearly indicated that over-expression of IOMT in infected alfalfa leaves leads to earlier induction and increased levels of formononetin glucoside and medicarpin compared to control lines (Fig. 6E and 6F).

Sense transformant # 78 had a high transgene copy number but did not express IOMT protein in the leaves (Fig. 3B). It appeared to exhibit epigenetic gene silencing (Matzke, M.A. and A.J. M. Matzke. 1995. "How and why do plants inactivate homologous (trans)genes?" *Plant Physiol* 107: 679-685). Analysis of replicate cuttings of line #78 and empty vector control line #56C indicated that, following infection with *P. medicaginis*, induction of formononetin glucoside and medicarpin in line #78 was significantly less than in the control plants (Fig. 7A and 7B). Overall, the reductions were by 65% for formononetin conjugate and 58% for medicarpin, and this reflected the relative IOMT activities in plants of the two lines. Thus, the data on the up- and down- regulation of IOMT in elicited or infected alfalfa leaves indicate that, if the remainder of the isoflavonoid pathway is induced, IOMT functions operationally in the formation of 4'-O-methylated

isoflavonoids (formononetin and medicarpin in alfalfa) rather than as a 7-*O*-methyltransferase producing isoformononetin.

Phoma medicaginis is a successful pathogen of alfalfa, leading to disease symptoms on the cultivar (Regen SY) used for the genetic transformation. To determine whether the more rapid accumulation of the phytoalexin medicarpin leads to resistance to *Phoma* in plants over-expressing IOMT, IOMT over-expressing and control plants were inoculated on the leaves using a pin wheel to produce a line of small wounds, into which fungal spores would enter to initiate infection on the susceptible alfalfa cultivar. The sizes of the brown *Phoma* lesions were then measured at 5 days post-infection. The results showed that the lesion size was much reduced in the IOMT over-expressing lines #67 and #69 compared to the controls. Measurement of multiple lesions five days after infection gave an average lesion size of 0.96 mm (n = 100) for control plants and 0.41 mm (n = 100) for line #69, and 0.46 mm (n = 100) for IOMT over-expressing line #67 compared to 1.17 mm (n = 100) for the corresponding control line grown and infected in parallel, as shown in Fig. 8A and 8B. Thus, transgenic over-expression of IOMT is a viable strategy for engineering disease resistance in alfalfa, and, by analogy, in other plants in which 4'-*O*-methylated isoflavonoids serve as phytoalexins.

Taken together, the results of the enzyme assays, feeding, elicitation and infection studies with transgenic alfalfa indicate that IOMT methylates the 7-position of daidzein to produce isoformononetin from exogenously supplied daidzein both in vitro and in planta, but is involved in 4'-position specific methylation to produce formononetin when the daidzein is supplied through the endogenous isoflavonoid pathway in planta. By performing reverse genetic experiments to modify expression of the enzyme in transgenic plants that naturally contain this enzyme, this unusual differential regiospecificity of IOMT in vivo compared to in vitro has now been found.

Up- and down-regulation of IOMT expression in transgenic alfalfa has quantitatively corresponding effects on the levels of 4'-*O*-methylated isoflavonoids, indicating that IOMT operates functionally as a rate limiting enzyme for the synthesis of these compounds in alfalfa. In contrast, it has been previously reported that the major rate-limiting step in isoflavonoid biosynthesis is at the entry point into the isoflavonoid branch pathway catalyzed by the isoflavone synthase cytochrome P450 (Steele et al. 1999. "Molecular

characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean," *Arch Biochem Biophys* 367: 146-150; and Jung, et al. 2000. "Identification and expression of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes," *Nature Biotechnology* 18: 208-212).

5 The above data suggest that increased production of 4'-O-methylated isoflavonoids and resultant disease resistance in IOMT over-expressing plants might be the direct result of elevated IOMT levels, and, therefore, point to a direct involvement of IOMT in the synthesis of these compounds as a rate limiting step. However, because the 4'-O-methylated compounds are stress-induced phytoalexins in alfalfa, it is possible that lines with elevated

10 IOMT activity have some kind of metabolic stress that leads to increased phytoalexin production, independent of flux through IOMT. This is unlikely in view of the lack of detectable phytoalexins in unelicited or uninfected IOMT over expressing plants (Fig. 5C and 5D, and Fig. 6C and 6D). To further rule out this possibility, and to determine whether other enzymes of the isoflavonoid pathway might be modulated following expression of

15 IOMT, we examined the levels of transcripts encoding eight of the enzymes involved in the conversion of phenylalanine to medicarpin in a control and an IOMT over-expressing line as a function of time following infection with *P. medicaginis*. The results in Table I confirm, firstly, that IOMT transcripts were constitutively high in line #69 in the absence of *Phoma* infection, consistent with the transgene being under control of the 35S promoter. In

20 uninfected leaves ectopically expressing IOMT, the levels of transcripts of the other enzymes of the phenylpropanoid/isoflavonoid pathway were not significantly elevated above control levels. Thus, over-expression of IOMT does not, of itself, induce the isoflavonoid pathway as a stress response, consistent with the metabolic profile data of Figures 5 and 6.

RNA gel blot analysis of isoflavonoid pathway transcripts in *Phoma* infected leaves

25 of empty vector control (line #64C) and IOMT over-expressing (line #69) alfalfa using labeled cDNA for various enzymes in the isoflavonoid pathway is given in Table I. Total RNA was isolated from leaves at 6, 24 and 48 hours after infection with *P. medicaginis* (Lane P) or treatment with water (Lane W), and probed with labeled cDNA probes for alfalfa PAL, alfalfa C4H, alfalfa acetyl CoA carboxylase, alfalfa CHI, *Medicago truncatula*

30 IFS, alfalfa IOMT, *Medicago truncatula* I2'OH and alfalfa IFR. Blots were stripped and re-probed with a ribosomal RNA probe to check loading and transfer efficiency. Following

infection with *Phoma*, there was a weak, relatively slow induction of phytoalexin pathway enzyme transcripts in empty vector control alfalfa leaves. This response is typical of that found in compatible interactions (Lamb, et al.1992. "Emerging strategies for enhancing crop resistance to microbial pathogens," *Bio/technology* 10: 1436-1445). However, the levels of transcripts encoding phenylalanine ammonia-lyase (PAL), cinnamate 4-hydroxylase (C4H), and isoflavone reductase (IFR) were much greater in IOMT over-expressing Line #69 than in the control line by 12 hours post-infection. These transcripts were also significantly induced in Line #69 by 6 hours post-infection, whereas IFS and IFR transcripts remained uninduced by 6 hours post-treatment in the control. Levels of chalcone isomerase (CHI) and isoflavone 2'-hydroxylase (I2'OH) transcripts were slightly elevated in Line #69 compared to the control following infection. In contrast, transcripts encoding cytosolic acetyl CoA carboxylase, the enzyme that provides malonyl CoA for the chalcone synthase reaction and that is co-induced as part of the phytoalexin response in elicited alfalfa cells (Shorrosh, et al. 1994. "Molecular cloning, characterization and elicitation of acetyl-CoA carboxylase in alfalfa," *Proc Natl Acad Sci USA* 91:4323-4327), were not significantly higher in Line #69 than in the empty vector control line under any of the treatments.

Table I: RNA Gel Blot Analysis of Isoflavonoid Pathway Transcripts in *Phoma* Infected Leaves of Empty Vector Control (Control)^a and IOMT Over-expressing (Line #69) Alfalfa Over Time^b

Enzyme ^c	Line	Time post-treatment					
		6 hours		12 hours		24 hours	
		<i>Phoma</i> infection	Water treatment	<i>Phoma</i> infection	Water treatment	<i>Phoma</i> infection	Water treatment
PAL	#69	7	1	9	1	4	4
	Control	4	1	6	1	4	1
C4H	#69	7	4	9	3	5	5
	Control	2	1	7	1	2	1
ACC	#69	4	2	7	5	4	4
	Control	4	4	7	2	4	2
CHI	#69	7	7	9	6	6	0
	Control	6	6	8	5	6	1

Enzyme ^c	Line	Time post-treatment					
		6 hours		12 hours		24 hours	
		<i>Phoma</i> infection	Water treatment	<i>Phoma</i> infection	Water treatment	<i>Phoma</i> infection	Water treatment
IFS	#69	2	0	7	2	6	2
	Control	0	0	6	0	3	1
IOMT	#69	3	3	3	3	3	3
	Control	0	0	3	0	1	0
I2'OH	#69	6	4	9	4	5	4
	Control	4	4	9	1	4	1
IFR	#69	6	0	9	0	7	1
	Control	0	0	7	0	1	0

^a Control = Line #64C.

^b Results of RNA gel blots are reported in terms of relative intensity of bands.

^c Enzymes: alfalfa PAL (L-phenylalanine ammonia-lyase); alfalfa C4H (cinnamate 4-hydroxylase); alfalfa ACC (cytosolic acetyl CoA carboxylase); alfalfa CHI (chalcone isomerase); *Medicago truncatula* IFS (isoflavone synthase); alfalfa IOMT (isoflavone-*O*-methyltransferase); *Medicago truncatula* I2'OH (isoflavone 2'-hydroxylase); and alfalfa IFR (isoflavone reductase).

In various embodiments, IOMT genes can be introduced into plants by standard plant transformation strategies including, but not limited to, *Agrobacterium*-mediated transformation (Horsch, B. et al. 1985. "A simple and general method for transferring genes into plants," *Science* 227: 1229-1231) or particle bombardment (Klein, et al. 1988. "Stable genetic transformation of intact *Nicotiana* cells by the particle bombardment process," *Proc Natl Acad Sci USA* 85: 8502-8505).

In the present invention, any polynucleotide encoding IOMT having the property to induce the production of 4-*O*-methylated phytoalexins, nutraceuticals, their conjugates or mixtures thereof can be utilized. A polynucleotide encoding IOMT useful in the present invention includes the sequence in SEQ ID NO:1 and Fig. 2, polynucleotides encoding dominant negative forms of IOMT, and nucleic acid sequences complementary to the

sequence in SEQ ID NO:1 and Fig. 2. A complementary sequence may include an antisense nucleotide. When the sequence is RNA, the deoxynucleotides A, G, C, and T of the sequence in SEQ ID NO:1 and Fig. 2 are replaced by ribonucleotides A, G, C, and U, respectively. Also included in the invention are fragments of the above-described nucleic acid sequences which are of sufficient nucleotide length to permit the fragment to selectively hybridize to DNA that encodes the protein of the sequence in SEQ ID NO:1 and Fig. 2 under physiological conditions or a close family member of IOMT. Degenerate variants of the sequence in SEQ ID NO:1 and Fig. 2, the sequence in SEQ ID NO:1 and Fig. 2 where T can also be a U, and fragments of these sequences that will hybridize to DNA or RNA which encodes IOMT are also included. The term "selectively hybridize" refers to hybridization under moderately or highly stringent conditions which excludes non-related nucleotide sequences.

Rate control by IOMT allows for manipulation of IOMT expression to drive increased accumulation of antimicrobial phytoalexins as a mechanism for improved plant disease resistance, or to increase or decrease the levels and/or methylation status of isoflavones. Isoflavones are valuable as nutraceuticals (Adlercreutz, H. and W. Mazur. 1997. "Phyto-estrogens and western diseases," *Ann Med* 29: 95-120), and are naturally limited to the leguminosae, where they occur with the 4'-hydroxyl group methylated (formononetin and biochanin A) or free (daidzein and genistein). Modification of IOMT expression in vivo can be used to alter the 4'-O-methylation of a plant's isoflavones. As used herein, 4'-O-isoflavonoid phytoalexins include but are not limited to medicarpin, maackiain, pisatin, their respective conjugates, or mixtures thereof; and 4'-O-methylated isoflavonoid nutraceuticals include but are not limited to formononetin, biochanin A, texasin, afromosin, pseudobaptigenin, their respective conjugates, or mixtures thereof. Increases in levels of 4'-O-isoflavonoid phytoalexins and 4'-O-methylated isoflavonoid nutraceuticals can be made by over-expression of the IOMT gene in transgenic plants which naturally make these compounds and by expression of the IOMT gene in transgenic plants which naturally do not make these compounds. Furthermore, 4'-O-methylated isoflavonoid nutraceuticals can be produced in non-plant systems (including but not limited to transfected bacterial, yeast or insect cells which have been genetically transformed to contain all the other necessary enzymes of isoflavonoid biosynthesis) by expression of the IOMT gene under the control of a suitable constitutive or inducible promoter using methods known in

the art (Frick, S., Kutchan, T.M. 1999. "Molecular cloning and functional expression of O-methyltransferases common to isoquinoline alkaloid and phenylpropanoid biosynthesis," *Plant J* 17: 329-339; Batard, et al. 1998. "Molecular cloning and functional expression in yeast of CYP76B1, a xenobiotic-inducible 7-ethoxycoumarin O-de-ethylase from *Helianthus tuberosus*," *Plant J* 14: 111-120).

The present invention also includes a composition comprising at least one 4'-O-methylated isoflavonoid suitable for administration as a food stuff, a nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical, wherein the source of the 4'-O-methylated isoflavonoid is a transgenic plant expressing an isoflavone O-methyltransferase gene of the present invention. A portion of the transgenic plant comprising the 4'-O-methylated isoflavonoid or 4'-O-methylated isoflavonoid extracted from the transgenic plant can be utilized.

For down-regulation of IOMT in plants that naturally make 4'-O-isoflavonoid phytoalexins and 4'-O-methylated isoflavonoid nutraceuticals, IOMT gene sequences can be transformed in the antisense orientation (Bourque, J. E. 1995. "Antisense strategies for genetic manipulations in plants," *Plant Sci* 105: 125-149) or expressed from vectors designed to activate gene silencing (Angell, S.M. and D.C. Baulcombe. 1997. "Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA," *EMBO J* 16: 3675-3684). IOMT sequences used can be the alfalfa IOMT8 designated in SEQ ID NO:1 and Fig. 2, or any other IOMT gene with in vivo 4'-O-methylation specificity that could be isolated by hybridization techniques using IOMT8 as a probe.

Isoflavonoid compounds methylated at the 7-position (e.g., isoformononetin and prunetin) may also have nutraceutical activity, and the alfalfa IOMT can be used for making these compounds by feeding non-methylated isoflavone precursors to intact plants, plant cell suspension cultures, or non-plant systems (including but not limited to transfected bacterial, yeast or insect cells which have been genetically transformed to contain all the other necessary enzymes of isoflavonoid biosynthesis) which have been transformed with an IOMT gene under the control of a suitable constitutive or inducible promoter. Alternatively, the 7-O-methylated isoflavonoid compounds can be produced using in vitro processes by contacting non-methylated isoflavone precursors with isolated soluble or immobilized isoflavone-O-transferase enzyme which has been produced and isolated from transgenic

plants, plant cell suspension cultures or a non-plant system (including but not limited to transfected bacterial, yeast or insect cells which have been genetically transformed to contain all the other necessary enzymes of isoflavonoid biosynthesis). As used herein, 7-*O*-methylated isoflavonoid compounds include but are not limited to isoformononetin, prunetin, their respective conjugates, or mixtures thereof.

WE CLAIM:

1. A method for increasing the level of at least one 4'-*O*-methylated isoflavonoid compound in a target plant comprising transforming said target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic plant and over-expressing said gene in said transgenic plant under the control of a suitable constitutive or inducible promoter.
2. The method of claim 1, wherein said compound is a 4'-*O*-methylated isoflavonoid phytoalexin.
3. The method of claim 1, wherein said compound is a 4'-*O*-methylated isoflavonoid nutraceutical.
4. The method of claim 1, 2 or 3, wherein said fragment comprises SEQ ID NO:1.
5. The method of claim 1, 2 or 3, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.
6. A method for producing at least one 4'-*O*-methylated isoflavonoid compound in a target plant that does not produce said 4'-*O*-methylated isoflavonoid compound comprising transforming said target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic plant and expressing said isoflavone *O*-methyltransferase gene in said transgenic plant under the control of a suitable constitutive or inducible promoter, said transgenic plant containing all the other necessary enzymes of isoflavonoid biosynthesis to produce said 4'-*O*-methylated isoflavonoid compound.
7. The method of claim 6, wherein said compound is a 4'-*O*-methylated isoflavonoid phytoalexin.
8. The method of claim 6, wherein said compound is a 4'-*O*-methylated isoflavonoid nutraceutical.
9. The method of claim 6, 7 or 8, wherein the native DNA of said target plant encodes said enzymes.

10. The method of claim 6, 7 or 8, wherein said target plant is genetically transformed to encode for at least one said enzyme

11. The method of claim 9, wherein said fragment comprises SEQ ID NO:1.

12. The method of claim 9, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

13. The method of claim 10, wherein said fragment comprises SEQ ID NO:1.

14. The method of claim 10, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

15. A method for producing at least one 4'-*O*-methylated isoflavonoid nutraceutical in non-plant cell system by expression of a DNA fragment comprising an isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter in cells that have been genetically transformed to contain all the other necessary enzymes of isoflavonoid biosynthesis to make said 4'-*O*-methylated isoflavonoid nutraceutical.

16. The method of claim 15, wherein said fragment comprises SEQ ID NO:1.

17. The method of claim 15, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

18. A method for decreasing the levels of formononetin, at least one of its conjugates or mixtures thereof in a transgenic forage legume comprising antisense expression, sense gene-mediated silencing, or nucleic acid-mediated insertional inactivation of a DNA fragment comprising an isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter.

19. The method of claim 18, wherein said fragment comprises SEQ ID NO:1.

20. The method of claim 18, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

21. The method of claim 18, 19 or 20, wherein said legume is alfalfa.

22. A method for decreasing the level of at least one 4'-*O*-methylated isoflavonoid compound in a target plant having all the necessary enzymes for synthesizing said 4'-*O*-methylated isoflavonoid compound comprising transforming said target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic
5 plant and inducing antisense expression, sense gene-mediated silencing, or nucleic acid-mediated insertional inactivation of said isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter.

23. The method of claim 22, wherein said compound is selected from the group consisting of a 4'-*O*-methylated isoflavonoid phytoalexin, a 4'-*O*-methylated isoflavonoid phytoalexin conjugate and mixtures thereof.

24. The method of claim 22 or 23, wherein said fragment comprises SEQ ID NO:1.

25. The method of claim 22 or 23, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

26. A method for decreasing the level of at least one 4'-*O*-methylated isoflavonoid nutraceutical, at least one 4'-*O*-methylated isoflavonoid nutraceutical or mixtures thereof in a target plant having all the necessary enzymes for synthesizing said 4'-*O*-methylated isoflavonoid nutraceutical or said conjugate comprising transforming said
5 target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene to form a transgenic plant and inducing antisense expression or sense gene-mediated silencing of said isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter, thereby increasing the level of the corresponding non-methylated precursor, its conjugate or mixture thereof.

27. The method of claim 26, wherein said fragment comprises SEQ ID NO:1.

28. The method of claim 26, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

29. A method for the production of a 7-*O*-methylated isoflavonoid compound comprising contacting intact plants or cell suspension cultures with a non-methylated isoflavone precursor of said 7-*O*-methylated isoflavonoid compound, said intact plants or

cell suspension cultures transformed with a DNA fragment comprising an isoflavone *O*-methyltransferase gene under the control of a suitable constitutive or inducible promoter.

30. The method of claim 29, wherein said fragment comprises SEQ ID NO:1.

31. The method of claim 29, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

32. A method for the production of a 7-*O*-methylated isoflavonoid compounds comprising contacting a soluble or immobilized isoflavone *O*-methyltransferase enzyme with a non-methylated isoflavone precursor to said 7-*O*-methylated isoflavonoid compound, wherein said enzyme is produced by the expression of a DNA fragment
5 encoding the isoflavone *O*-methyltransferase gene in transgenic plants, transfected yeast, or transfected insect cells.

33. The method of claim 32, wherein said fragment comprises SEQ ID NO:1.

34. The method of claim 32, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

35. A method to detect 4'-*O*-methyltransferase comprising the steps of
a) preparing tissue that may have 4'-*O*-methyltransferase;
b) incubating said tissue with a first antibody that binds 4'-*O*-methyltransferase;
5 c) removing said antibody that did not bind to said tissue; and
d) incubating said tissue with a second antibody that binds said first antibody, said second antibody being detectably labeled.

36. A method of increasing disease resistance in a target plant by transforming said target plant with a DNA fragment comprising an isoflavone *O*-methyltransferase gene, wherein said transformed plant exhibits increased levels of at least one 4'-*O*-methylated isoflavonoid when compared to levels of said 4'-*O*-methylated isoflavonoid
5 in plants of the same species which do not comprise said DNA fragment.

37. The method of claim 36, wherein said fragment comprises SEQ ID NO:1.

11137/04803

38. The method of claim 36, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

39. In a composition comprising at least one 4'-*O*-methylated isoflavonoid suitable for administration as a foodstuff, a nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical, the improvement comprising 4'-*O*-methylated isoflavonoid isolated from at least a portion of a transgenic plant transformed
5 with a DNA fragment comprising an isoflavone *O*-methyltransferase gene, wherein said transgenic plant exhibits increased levels of said 4'-*O*-methylated isoflavonoid when compared to levels of said 4'-*O*-methylated isoflavonoid in plants of the same species which do not comprise said DNA fragment.

40. The composition of claim 39, wherein said fragment comprises SEQ ID NO:1.

41. The composition of claim 39, wherein said fragment comprises a sequence exhibiting at least moderate hybridization with SEQ ID NO:1.

42. The composition of claim 39, 40 or 41, wherein said transgenic plant is a legume.

43. A transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said transgenic plant upon expression of said gene exhibits increased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid
5 compounds in plants of the same species which do not comprise said recombinant DNA sequence.

44. Seed from a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said plant upon expression of said gene exhibits increased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid
5 compounds in plants of the same species which do not comprise said recombinant DNA sequence.

11137/04803

45. Progeny from a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said plant upon expression of said gene exhibits increased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise said recombinant DNA sequence.

46. Progeny from seed of a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said plant upon expression of said gene exhibits increased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise said recombinant DNA sequence.

47. A transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said plant upon expression of said gene exhibits decreased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise said recombinant DNA sequence.

48. Seed from a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said plant upon expression of said gene exhibits decreased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise said recombinant DNA sequence.

49. Progeny from a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said plant upon expression of said gene exhibits decreased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise said recombinant DNA sequence.

11137/04803

50. Progeny from seed of a transgenic plant comprising at least one recombinant DNA sequence encoding a portion of an isoflavone *O*-methyltransferase gene, wherein said plant upon expression of said gene exhibits decreased levels of 4'-*O*-methylated isoflavonoid compounds when compared to levels of said 4'-*O*-methylated isoflavonoid compounds in plants of the same species which do not comprise said recombinant DNA sequence.




Fig. 1

```

ccaaatttca tttgaaaaaa aaaaatggct tcatcaatta atggccgaaa accaagtgaa 60
attttcaaag cacaagcttt attatacaaa catatatatg cttcataga ttccatgtct 120
cttaaatggg ctgttgaaat gaacataacca aacataatcc aaaaccatgg caaaccaatt 180
tctctttcaa acttagtttc aattcttcaa gttccatcgt cgaaaatagg taacgtgcgg 240
cgtctcatgc gttacctcgc gcacaacgga ttcttcgaga taattacaaa agaagaagag 300
tcttatgctc tcactgttgc ttcagagctt cttgttagag gcagtgatct ttgttttagca 360
ccaatggttg agtgtgttct tgatccaact ctttcggggt cgtatcatga gctgaagaaa 420
tggatttatg aggaagatct tacactcttt ggtgttactt taggatctgg tttttgggat 480
tttcttgata aaaatcctga atataatacc tcatttaatg atgcaatggc tagtgattct 540
aaattgataa acttggcatt gagagattgt gattttgtgt ttgatggatt ggaatcaatt 600
gtggatgttg gtggtggaac tggacaact gctaagatta tttgtgagac ttttcctaag 660
ttgaaatgta ttgtgtttga taggccacaa gttgtagaga acttatctgg aagcaataat 720
ttgacttatg ttggtgggga catgttcaca tctattccta atgctgatgc agttttgctt 780
aagtatatcc tacataattg gactgataag gattgcctaa ggatactgaa gaaatgtaaa 840
gaagctgtta caaatgatgg gaaaagagga aaagtgacta ttatagacat ggtgatagat 900
aaaaaaaaag atgagaatca agttactcaa attaagctcc ttatggatgt aaacatggct 960
tgtctaaatg gaaaagagag aaatgaggaa gaatggaaga aactcttcat agaagctggg 1020
ttccaacact ataagatatc tcttttgact ggatttttgt ctcttattga gatctatcca 1080
taaacacttt tgctttgatc attcatccat tctattgttt catgttataa accaatcttg 1140
ttctctatta tgatatctca cttgtaatat gcatttggtg gtaacaaata atagaatttg 1200
catacatgta tgatttttaa aaaaaaaaaa a
1231

```

Fig. 2

3/11

3/11




Fig. 3A




Fig. 3B




Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4D




Fig. 4E




Fig. 4F




Fig. 5A




Fig. 5B




Fig. 5C







Fig. 5D






Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6D

09/926571




Fig. 6E




Fig. 6F




Fig. 7A




Fig. 7B

11/11




Fig. 8A




Fig. 8B

DECLARATION AND POWER OF ATTORNEY

COPY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, that I believe that I am the original, first and sole inventor (if only one name is listed below) or I believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention, design or discovery entitled **ISOFLAVONOID METHYLATION ENZYME**, the specification of which (check one)

- ☐ is attached hereto; or
☒ was filed on **May 15, 2000**, as PCT International Application Number
PCT/US00/13389
☐ and was amended on

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; that I do not know and do not believe that said invention, design or discovery was ever known or used in the United States of America before my invention or discovery thereof, or patented or described in any printed publication in any country before my invention or discovery thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application; that said invention, design or discovery has not been patented or made the subject of an inventor's certificate issued prior to the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns; and that I acknowledge the duty to disclose information of which I am aware which is material to the examiner of this application in accordance with 37 C.F.R. § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

NUMBER	COUNTRY	DATE FILED	PRIORITY CLAIMED
--------	---------	------------	------------------

N/A

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION SERIAL NO.

U.S. 60/135,026

DATE FILED

May 20, 1999

I hereby claim the benefit under 35 U.S.C. § 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States Application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	DATE FILED	STATUS
N/A		

I hereby appoint:

Eugenia S. Hansen
Karen L. Knezek
Rod A. Cooper

Reg. No. 31,966
Reg. No. 39,253
Reg. No. 42,436

(3)

all of the firm of Sidley, Austin, Brown and Wood, my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, and to file and prosecute any international patent applications filed thereon before any international authorities under the Patent Cooperation Treaty.

Send correspondence to:

Eugenia S. Hansen
Sidley, Austin, Brown & Wood
717 N. Harwood, Suite 3400
Dallas, TX 75201

Direct telephone calls to:

Eugenia S. Hansen
at (214) 981-3315
Atty. Docket No. 11137/04808

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or joint inventor: Richard A. Dixon

Inventor's signature: Richard A. Dixon

Date: 11/19/01 OK

Residence (City, County, State): Ardmore, Carter County, Oklahoma

Citizenship: United States of America

Post Office Address: 206 Woods Lane, Ardmore, Oklahoma 73401

2-00
Full name of sole or joint inventor: **Xian Z. He**

Inventor's signature: _____

Xian Z. He

Date: _____

11-16-01

OK

Residence (City, County, State): **Ardmore, Carter County, Oklahoma**

Citizenship: **United States of America**

Post Office Address: **316 Beaumont Drive, Ardmore, Oklahoma 73402**

2002-11-16-01

COPY

Applicant or Patentee: **Richard A. Dixon, et al.**

Serial or Patent No.:

Filed or Issued:

Attorney's Docket No.: **11137/04808**

For: **ISOFLAVONOID METHYLATION ENZYME**

**VERIFIED STATEMENT (DECLARATION)
CLAIMING SMALL ENTITY STATUS
(37 C.F.R. §§ 1.9(f) and 1.27(d))
NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: **The Samuel Roberts Noble Foundation, Inc.**

ADDRESS OF ORGANIZATION: 2510 Sam Noble Parkway, Ardmore, Oklahoma 73401

TYPE OF ORGANIZATION

- () UNIVERSITY OR OTHER INSTITUTE OF HIGHER EDUCATION
- (X) TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. §§ 501(a) and 501(c)(3))
- () NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE)
(CITATION OF STATUTE)
- () WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. §§ 501(a) AND 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
- () WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE)
(CITATION OF STATUTE)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(e) for purposes of paying reduced fees under §§ 41(a) and (b) of Title 35, United States Code, with regard to the invention entitled **ISOFLAVONOID METHYLATION ENZYME** by inventors **Richard A. Dixon and Xian Z. He** described in

- ☐ the specification filed herewith.
- ☒ PCT International Application No. PCT/US00/13389, filed May 15, 2000.
- ☐ patent no. , issued .

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above-identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below* and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

- ☒ no such person, concern or organization
- ☐ persons, concerns or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27)

NAME: N/A

ADDRESS:

☐ individual ☐ small business concern ☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: **Michael A. Cawley**

TITLE IN ORGANIZATION: **President and CEO**

ADDRESS OF PERSON SIGNING: **2510 Sam Noble Parkway, Ardmore OK 73401**

SIGNATURE

Michael A. Cawley

MC

DATE

11.19.01

09267-49260